DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on September 11, 2008; DOI: 10.1124/dmd.108.022764


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.022764v1
36/12/2564    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by He, K.
Right arrow Articles by Christopher, L. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, K.
Right arrow Articles by Christopher, L. J


Received for publication June 9, 2008.
Revised September 9, 2008.
Accepted for publication September 10, 2008.

Lacteal Excretion, Fetal and Maternal Tissue Distribution of Dasatinib in Rats

Kan He 1*, Michael W Lago 2, Ramaswamy A Iyer 1, Wen-Chyi Shyu 1, William G Humphreys 1, Lisa J Christopher 1

1 BMS 2 Bristol-Myers Squibb

* Address correspondence to: E-mail: higkan{at}gmail.com

Abstract

Dasatinib (SPRYCEL®, BMS-354825) is a potent and broad spectrum kinase inhibitor, used for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Dasatinib exhibited extensive lacteal excretion in Sprague-Dawley rats following a single oral dose of [14C]-dasatinib (10 mg/kg, 300 µCi/kg). Radioactivity was detected through 72 hours post-dose, with a milk/plasma AUC0-inf ratio of approximately 25. The majority of the total radioactivity in milk was attributed to unchanged dasatinib. Following a single dose of [14C]-dasatinib to pregnant Sprague-Dawley rats at gestation day 18, radioactivity was extensively distributed in maternal tissues. The radioactivity detected by tissue excision or quantitative whole body autoradiography was highest in adrenal gland, mammary tissue, lungs, kidneys, liver and placenta. Compared with maternal tissues, a relatively low level of radioactivity was detected in fetal tissues. The concentrations of dasatinib-equivalents in fetal liver and kidneys were <13% of the respective maternal organs. The Cmax of the dasatinib-equivalents in fetal blood was approximately 39% of that in maternal blood, however, the AUC values were comparable. Fetal brain/blood ratios of Cmax and AUC0-inf were approximately 1.58 and 1.48, respectively, which were much greater than the maternal ratios of 0.12 and 0.13. In summary, dasatinib is extensively distributed in maternal tissues and secreted into milk, but its penetration into the adult brain was limited. Transporters may be involved in mediating dasatinib distribution in the adult rat, while in the fetus, tissue and blood exposures were similar, suggesting that distribution in the fetus is predominantly medited by diffusion.


Key words: active transport, blood-brain barrier, distribution, drug distribution, drug secretion, reproductive toxicology





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.